Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.

European journal of pharmacology - 5 Jul 2013

Tandon Ruchi, Senthil V, Nithya D, Pamidiboina Venu, Kumar Ankur, Malik Sumit, Chaira Tridib, Diwan Manish, Gupta Praful, Venkataramanan R, Malik Renu, Das Biswajit, Dastidar Sunanda G, Cliffe Ian, Ray Abhijit, Bhatnagar Pradip Kumar

Abstract excerpt

Pharmacological intervention of epidermal growth factor receptor (EGFR) family members by antibodies or small molecule inhibitors has been one of the most successful approaches for anticancer therapy. However this therapy has its own limitations due to the development of resistance, over a period of time. One of the possible causes of the development of resistance to the therapy with EGFR inhibitors could be the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Stability
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HT29 Cells

Share to Membrane Potential, Mitochondrial

Share to Microsomes, Liver

Share to Pyrazoles

Share to Quinazolines

Share to Receptor, IGF Type 1

Source

Identifiers

PMID: 23639757
DOI: 10.1016/j.ejphar.2013.04.016

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.PMID 23639757Read ↗

Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.Semantic proximity Read ↗

Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancerSemantic proximity Read ↗

Emerging combination therapies to overcome resistance in EGFR-driven tumors.Semantic proximity Read ↗

Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review.Semantic proximity Read ↗

The Mechanisms of Differential Sensitivity to an Insulin-like Growth Factor-1 Receptor Inhibitor (BMS-536924) and Rationale for Combining with EGFR/HER2 InhibitorsSemantic proximity Read ↗

Drugging IGF-1R in cancer: New insights and emerging opportunitiesSemantic proximity Read ↗

Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonistsSemantic proximity Read ↗

Rational bases for the development of EGFR inhibitors for cancer treatment.Semantic proximity Read ↗

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapySemantic proximity Read ↗

Targeting the EGFR and the PKB pathway in cancer.Semantic proximity Read ↗

[EGFR pathway and mechanism of action of tyrosine kinase inhibitors].Semantic proximity Read ↗

Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.